{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T08:17:00Z","timestamp":1790669820177,"version":"4.1.0"},"reference-count":50,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2019,3,21]],"date-time":"2019-03-21T00:00:00Z","timestamp":1553126400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0213940","type":"journal-article","created":{"date-parts":[[2019,3,21]],"date-time":"2019-03-21T17:41:22Z","timestamp":1553190082000},"page":"e0213940","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":55,"title":["Anticoagulant therapy for acute venous thrombo-embolism in cancer patients: A systematic review and network meta-analysis"],"prefix":"10.1371","volume":"14","author":[{"given":"Anne","family":"Rossel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helia","family":"Robert-Ebadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Combescure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Grosgurin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Stirnemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Addeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Garin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Agoritsas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7528-7363","authenticated-orcid":true,"given":"Jean-Luc","family":"Reny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2016-6759","authenticated-orcid":true,"given":"Christophe","family":"Marti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2019,3,21]]},"reference":[{"issue":"11","key":"ref1","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1001\/archinte.162.11.1245","article-title":"Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study","volume":"162","author":"JA Heit","year":"2002","journal-title":"Arch Intern Med"},{"issue":"6","key":"ref2","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/jama.293.6.715","article-title":"Malignancies, prothrombotic mutations, and the risk of venous thrombosis","volume":"293","author":"JW Blom","year":"2005","journal-title":"JAMA"},{"issue":"2","key":"ref3","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report","volume":"149","author":"C Kearon","year":"2016","journal-title":"Chest"},{"issue":"10","key":"ref4","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1182\/blood-2002-01-0108","article-title":"Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis","volume":"100","author":"P Prandoni","year":"2002","journal-title":"Blood"},{"issue":"2","key":"ref5","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","article-title":"Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer","volume":"349","author":"AYY Lee","year":"2003","journal-title":"New England journal of medicine"},{"issue":"12","key":"ref6","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.amjmed.2006.02.022","article-title":"Long-term Low-Molecular-Weight Heparin versus Usual Care in Proximal-Vein Thrombosis Patients with Cancer","volume":"119","author":"RD Hull","year":"2006","journal-title":"American journal of medicine"},{"issue":"15","key":"ref7","doi-asserted-by":"crossref","DOI":"10.1001\/archinte.162.15.1729","article-title":"Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study","author":"G Meyer","year":"2002","journal-title":"Archives of internal medicine"},{"issue":"7","key":"ref8","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/jama.2015.9243","article-title":"Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: A randomized clinical trial","volume":"314","author":"AYY Lee","year":"2015","journal-title":"JAMA\u2014Journal of the American Medical Association"},{"key":"ref9","first-page":"CD006650","article-title":"Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer","volume":"6","author":"LA Kahale","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"ref10","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.thromres.2015.07.011","article-title":"Treatment of venous thromboembolism in patients with cancer: A network meta-analysis comparing efficacy and safety of anticoagulants","volume":"136","author":"F Posch","year":"2015","journal-title":"Thromb Res"},{"issue":"6","key":"ref11","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.thromres.2014.09.039","article-title":"Efficacy and safety of anticoagulant therapy for the treatment of acute cancer-associated thrombosis: a systematic review and meta-analysis","volume":"134","author":"M Carrier","year":"2014","journal-title":"Thromb Res"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.thromres.2016.07.013","article-title":"Evaluation of US prescription patterns: Are treatment guidelines for cancer-associated venous thromboembolism being followed?","volume":"145","author":"AA Khorana","year":"2016","journal-title":"Thromb Res"},{"issue":"5","key":"ref13","first-page":"805","article-title":"A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy","volume":"84","author":"G Palareti","year":"2000","journal-title":"Thromb Haemost"},{"issue":"9","key":"ref14","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"G Agnelli","year":"2013","journal-title":"N Engl J Med"},{"issue":"26","key":"ref15","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"R Bauersachs","year":"2010","journal-title":"N Engl J Med"},{"issue":"14","key":"ref16","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","article-title":"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism","volume":"366","author":"HR B\u00fcller","year":"2012","journal-title":"New England journal of medicine"},{"issue":"15","key":"ref17","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","article-title":"Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism","volume":"369","author":"HR B\u00fcller","year":"2013","journal-title":"New England journal of medicine"},{"issue":"24","key":"ref18","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"S Schulman","year":"2009","journal-title":"New England journal of medicine"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ijcard.2016.12.168","article-title":"Direct oral anti-coagulants compared with vitamin-K inhibitors and low-molecular-weight-heparin for the prevention of venous thromboembolism in patients with cancer: A meta-analysis study","volume":"230","author":"ND Brunetti","year":"2017","journal-title":"Int J Cardiol"},{"issue":"2","key":"ref20","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1378\/chest.14-0402","article-title":"Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis","volume":"147","author":"MC Vedovati","year":"2015","journal-title":"Chest"},{"issue":"7","key":"ref21","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism","volume":"378","author":"GE Raskob","year":"2018","journal-title":"N Engl J Med"},{"issue":"20","key":"ref22","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D)","volume":"36","author":"AM Young","year":"2018","journal-title":"J Clin Oncol"},{"issue":"4","key":"ref23","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Subcommittee on Control of Anticoagulation of the S, Standardization Committee of the International Society on T, Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"S Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"11","key":"ref24","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Subcommittee on Control of A. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH","volume":"13","author":"S Kaatz","year":"2015","journal-title":"J Thromb Haemost"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"JP Higgins","year":"2011","journal-title":"BMJ"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"f2914","DOI":"10.1136\/bmj.f2914","article-title":"Demystifying trial networks and network meta-analysis","volume":"346","author":"EJ Mills","year":"2013","journal-title":"BMJ"},{"issue":"4","key":"ref27","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/jrsm.1058","article-title":"Network meta-analysis, electrical networks and graph theory","volume":"3","author":"G. Rucker","year":"2012","journal-title":"Res Synth Methods"},{"issue":"5","key":"ref28","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.cct.2008.06.002","article-title":"Estimating the relative hazard by the ratio of logarithms of event-free proportions","volume":"29","author":"TV Perneger","year":"2008","journal-title":"Contemp Clin Trials"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"j3932","DOI":"10.1136\/bmj.j3932","article-title":"Multivariate and network meta-analysis of multiple outcomes and multiple treatments: rationale, concepts, and examples","volume":"358","author":"RD Riley","year":"2017","journal-title":"BMJ"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12874-015-0060-8","article-title":"Ranking treatments in frequentist network meta-analysis works without resampling methods","volume":"15","author":"G Rucker","year":"2015","journal-title":"BMC Med Res Methodol"},{"issue":"4","key":"ref31","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1177\/1076029606293692","article-title":"Secondary prevention of venous thromboembolic events in patients with active cancer: Enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period","volume":"12","author":"SR Deitcher","year":"2006","journal-title":"Clinical and applied thrombosis\/hemostasis"},{"issue":"3","key":"ref32","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.ejvs.2008.11.030","article-title":"A Randomised Open-Label Trial Comparing Long-term Sub-Cutaneous Low-Molecular-weight Heparin Compared with Oral-Anticoagulant Therapy in the Treatment of Deep Venous Thrombosis","volume":"37","author":"A Romera","year":"2009","journal-title":"European journal of vascular and endovascular surgery"},{"issue":"1","key":"ref33","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1067\/mva.2001.109336","article-title":"Low molecular weight heparin versus oral anticoagulants in the long-term treatment of deep venous thrombosis","volume":"33","author":"P L\u00f3pez-Beret","year":"2001","journal-title":"Journal of vascular surgery"},{"issue":"12","key":"ref34","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1111\/jth.13153","article-title":"Oral apixaban for the treatment of venous thromboembolism in cancer patients: Results from the AMPLIFY trial","volume":"13","author":"G Agnelli","year":"2015","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"1","key":"ref35","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1016\/S2352-3026(14)70018-3","article-title":"Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials","volume":"1","author":"MH Prins","year":"2014","journal-title":"Lancet Haematol"},{"issue":"8","key":"ref36","doi-asserted-by":"crossref","first-page":"e379","DOI":"10.1016\/S2352-3026(16)30057-6","article-title":"Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial","volume":"3","author":"GE Raskob","year":"2016","journal-title":"Lancet Haematol"},{"issue":"1","key":"ref37","first-page":"150","article-title":"Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer","volume":"114","author":"S Schulman","year":"2015","journal-title":"Thromb Haemost"},{"issue":"suppl_1","key":"ref38","first-page":"S39","article-title":"Venous thromboembolism: secondary prevention with dabigatran vs. acenocumarol in patients with paraneoplastic deep vein thrombosis","volume":"103","author":"L Mazilu IP","year":"2014","journal-title":"Results from a small prospective study in Romania"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.thromres.2018.08.023","article-title":"Efficacy and safety of anticoagulant agents in patients with venous thromboembolism and cancer: A network meta-analysis","volume":"170","author":"MC Vedovati","year":"2018","journal-title":"Thromb Res"},{"key":"ref40","article-title":"Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis","author":"A Li","year":"2018","journal-title":"Thromb Res"},{"issue":"Suppl 1","key":"ref41","first-page":"4631","article-title":"VTE recurrence and safety of Anticoagulants among patients with cancer treated for venous trhomboembolism","volume":"130","author":"A.A. MK Khorana","year":"2017","journal-title":"Blood"},{"key":"ref42","first-page":"1076029618800792","article-title":"Anticoagulation for the Treatment of Cancer-Associated Thrombosis: A Systematic Review and Network Meta-Analysis of Randomized Trials","author":"DM Sobieraj","year":"2018","journal-title":"Clin Appl Thromb Hemost"},{"issue":"6","key":"ref43","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1097\/MOG.0000000000000310","article-title":"Gastrointestinal bleeding secondary to the new anticoagulants","volume":"32","author":"NS Abraham","year":"2016","journal-title":"Curr Opin Gastroenterol"},{"issue":"4","key":"ref44","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1160\/TH16-11-0874","article-title":"Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin","volume":"117","author":"MP Brekelmans","year":"2017","journal-title":"Thromb Haemost"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ijcard.2016.11.117","article-title":"Major bleeding with vitamin K antagonists or direct oral anticoagulants in real-life","volume":"227","author":"C Becattini","year":"2017","journal-title":"Int J Cardiol"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.thromres.2016.02.028","article-title":"Edoxaban, a direct factor Xa inhibitor, suppresses tissue-factor induced human platelet aggregation and clot-bound factor Xa in vitro: Comparison with an antithrombin-dependent factor Xa inhibitor, fondaparinux","volume":"141","author":"Y Honda","year":"2016","journal-title":"Thromb Res"},{"issue":"5","key":"ref47","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1053\/j.gastro.2016.12.018","article-title":"Gastrointestinal Safety of Direct Oral Anticoagulants: A Large Population-Based Study","volume":"152","author":"NS Abraham","year":"2017","journal-title":"Gastroenterology"},{"issue":"1","key":"ref48","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/rth2.12002","article-title":"Current practice patterns and patient persistence with anticoagulant treatments for cancer-associated thrombosis","volume":"1","author":"AA Khorana","year":"2017","journal-title":"Res Pract Thromb Haemost"},{"issue":"5","key":"ref49","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ajh.25059","article-title":"Effectiveness and safety of anticoagulants for the treatment of venous thromboembolism in patients with cancer","volume":"93","author":"MB Streiff","year":"2018","journal-title":"Am J Hematol"},{"issue":"5","key":"ref50","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1177\/0962280210379172","article-title":"Meta-analysis of binary outcomes from two-by-two tables when the length of follow-up varies and hazards are proportional","volume":"20","author":"C Combescure","year":"2011","journal-title":"Stat Methods Med Res"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0213940","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T09:42:30Z","timestamp":1589017350000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0213940"}},"subtitle":[],"editor":[{"given":"Hugo","family":"ten Cate","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,3,21]]},"references-count":50,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,3,21]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0213940","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,21]]}}}